 |
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
ZIOPHARM Oncology to Present at the Canaccord Genuity 30th Annual Global Growth Conference
Aug 4, 2010
|
11.0 KB
|
| |
NEW YORK, Aug 04, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, MD, PhD, Chief Executive Officer, will present at the Canaccord
Genuity 30th Annual Global Growth Conference on Wednesday,
August 11, 2010 at 9:30 am ET at The Intercontinental Hotel in Boston,
MA. Dr...
|
|
|
ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical Programs
Jul 30, 2010
|
16.5 KB
|
| |
NEW YORK, Jul 30, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical cancer
company addressing unmet medical needs, today reported its financial
results for the three months ended June 30, 2010 and provided an update
on the Company's continued progress with its clinical programs.
For the sec...
|
|
|
ZIOPHARM Announces Initiation of Palifosfamide Pivotal Study
Jul 19, 2010
|
16.4 KB
|
| |
NEW YORK, Jul 19, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced the initiation of
the pivotal Phase III clinical trial for palifosfamide (ZymafosTM)
in patients with front-line metastatic soft tissue sarcoma. The study,
called PICASSO 3, is an international, randomized, double-blinded,
...
|
|
|
ZIOPHARM Provides Guidance on Planned Pivotal Phase III Study of Palifosfamide in Metastatic Soft Tissue Sarcoma
Jun 21, 2010
|
12.7 KB
|
| |
NEW YORK, Jun 21, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced guidance today
regarding the Company's planned pivotal Phase III trial for
palifosfamide in metastatic soft tissue sarcoma, including details of
the proposed study's design, timing and regulatory review.
Following reporting of favorab...
|
|
|
ZIOPHARM Announces 2010 Annual Meeting of Stockholders
Jun 17, 2010
|
9.4 KB
|
| |
NEW YORK, Jun 17, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will hold
its Annual Meeting of Stockholders on Wednesday, June 23, 2010 at 10:00
a.m. EST at the Grand Hyatt New York, Executive Board Room #1418.
Stockholders of record at the close of business on May 10, 2010 are
...
|
|
|
ZIOPHARM Set to Join Russell 3000(R) Index
Jun 14, 2010
|
13.7 KB
|
| |
NEW YORK, Jun 14, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will be
included in the broad-market Russell 3000(R) Index when Russell
Investments reconstitutes its comprehensive list of U.S. and global
equity indexes on June 25, 2010, according to a preliminary list of
addit...
|
|
|
ZIOPHARM Presents Positive Palifosfamide PICASSO Phase II Results in Oral Session at ASCO
Jun 7, 2010
|
13.4 KB
|
| |
NEW YORK, Jun 07, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire
Verschraegen of the University of New Mexico, Albuquerque and first
author of the abstract, "A phase II randomized controlled trial of
palifosfamide plus doxorubicin vs. doxorubicin in patients with soft
t...
|
|
|
-- ZIOPHARM Oncology to Present at Upcoming Investor Conferences --
Jun 2, 2010
|
12.1 KB
|
| |
NEW YORK, Jun 02, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it will
present at the following investor conferences on Wednesday June 9, 2010:
9th Annual Needham Healthcare ConferenceNew
York, NY10:40 a.m. ET
Jefferies 2010 Global Life Sciences ConferenceNew York, NY2:30
p.m. ET
ZIO...
|
|
|
ZIOPHARM Prices Common Stock Offering
May 27, 2010
|
8.6 KB
|
| |
NEW YORK, May 27, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced the pricing of an
underwritten public offering of 7,000,000 shares of its common stock at
a price to the public of $5.00 per share. The net proceeds from the sale
of the shares, after underwriting discounts and commissions and
...
|
|
|
ZIOPHARM Announces Proposed Public Offering of Common Stock
May 26, 2010
|
8.8 KB
|
| |
NEW YORK, May 26, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) today announced that it is
offering to sell shares of its common stock in an underwritten public
offering. Jefferies & Company, Inc. is acting as the sole book-running
manager for this offering. The co-manager for this offering is JMP
Se...
|
|
|
ZIOPHARM to Present Further Palifosfamide PICASSO Phase II Results in Oral Session at ASCO
May 21, 2010
|
12.9 KB
|
| |
NEW YORK, May 21, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire
Verschraegen of the University of New Mexico, Albuquerque, lead author
of the abstract on the palifosfamide study entitled, "A phase II
randomized controlled trial of palifosfamide plus doxorubicin vs.
dox...
|
|
|
ZIOPHARM Oncology to Present at the Rodman & Renshaw Annual Global Investment Conference
May 12, 2010
|
12.0 KB
|
| |
NEW YORK, May 12, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, MD, PhD, Chief Executive Officer, will present at the Rodman &
Renshaw Annual Global Investment Conference on Monday, May 17, 2010 at
9:50 am ET (14h50 BST) at The Grosvenor House Hotel in London, UK. Dr.
...
|
|
|
ZIOPHARM Oncology to Present at the Ninth Annual JMP Securities Research Conference
May 4, 2010
|
12.0 KB
|
| |
NEW YORK, May 04, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Jonathan
Lewis, MD, PhD, Chief Executive Officer, will present at the Ninth
Annual JMP Securities Research Conference on Monday, May 11, 2010 at
9:30 am PT at The Ritz-Carlton, San Francisco. Dr. Lewis will provide an
...
|
|
|
ZIOPHARM Reports First Quarter Financial Results
Apr 30, 2010
|
16.1 KB
|
| |
NEW YORK, Apr 30, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that
is seeking to develop and commercialize a diverse, risk sensitive
portfolio of in-licensed cancer drugs addressing unmet medical needs,
today reported its financial results for the three months ended March
...
|
|
|
ZIOPHARM Palifosfamide PICASSO Trial Abstract Selected for 2010 Best of ASCO(R) Meeting Program
Apr 22, 2010
|
13.4 KB
|
| |
NEW YORK, Apr 22, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that its
abstract, "A phase II randomized controlled trial of palifosfamide plus
doxorubicin vs. doxorubicin in patients with soft tissue sarcoma
(PICASSO)", to be presented at the 2010 ASCO Annual Meeting, has been
selec...
|
|
| |
Kristen Ann Carr Fund Awards Grant
Apr 21, 2010
|
22.9 KB
|
|
Darinaparsin Data Presented at AACR
Apr 20, 2010
|
12.6 KB
|
| |
WASHINGTON, Apr 20, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that preclinical
data on the novel organic arsenic darinaparsin (ZinaparTM, or
ZIO-101) were presented at the American Association for Cancer Research
(AACR) Annual Meeting in Washington, D.C. The presentation was from the
...
|
|
|
ZIOPHARM Commences Oral Indibulin Phase I/II Trial in Breast Cancer -- at Memorial Sloan-Kettering Cancer Center --
Apr 8, 2010
|
13.2 KB
|
| |
NEW YORK, Apr 08, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today it has initiated
a Phase I/II study at Memorial Sloan-Kettering Cancer Center for the
novel, mathematically - determined administration of oral indibulin
(Zybulin(TM) or ZIO-301) in the treatment of metastatic breast cancer.
Th...
|
|
|
ZIOPHARM Elects George B. Abercrombie, former CEO of Hoffmann-La Roche, to Board of Directors
Apr 6, 2010
|
13.0 KB
|
| |
NEW YORK, Apr 06, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today the appointment
of George B. Abercrombie to its Board of Directors. Mr. Abercrombie will
serve as a member of the Board's Compensation Committee as well as the
Nominating and Corporate Governance Committee. Additionally, Dr. Mur...
|
|
|
ZIOPHARM Reports Fourth Quarter and Full Year 2009 Financial Results
Mar 18, 2010
|
17.2 KB
|
| |
NEW YORK, Mar 18, 2010 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), a biopharmaceutical company that
is seeking to develop and commercialize a diverse, risk sensitive
portfolio of in-licensed cancer drugs addressing unmet medical needs,
announced today its financial results for the fourth quarter and full
...
|
|
|
| |
Recent Releases
Aug 4, 2010
ZIOPHARM Oncology to Present at the Canaccord Genuity 30th Annual Global Growth Conference
Jul 30, 2010
ZIOPHARM Reports Second Quarter Financial Results and Updates Clinical Programs
Jul 19, 2010
ZIOPHARM Announces Initiation of Palifosfamide Pivotal Study
more »
|
